Plaque psoriasis
Adult: In patients with moderate to severe cases who are candidates for systemic therapy or phototherapy: Initially, 100 mg at weeks 0 and 4, then every 8 weeks thereafter. Discontinue therapy if no response after 16 weeks.
Indications and Dosage
Subcutaneous
Plaque psoriasis Adult: In patients with moderate to severe cases who are candidates for systemic therapy or phototherapy: Initially, 100 mg at weeks 0 and 4, then every 8 weeks thereafter. Discontinue therapy if no response after 16 weeks.
|
Contraindications
Hypersensitivity. Clinically important active infections (e.g. TB, sepsis, hepatitis B). Concomitant use with live vaccines.
|
Special Precautions
Patient with history of chronic or recurrent infections, latent TB with unconfirmed adequate course of TB treatment. Pregnancy and lactation.
|
Adverse Reactions
Significant: Infections (e.g. upper respiratory tract infections, gastroenteritis, tinea infections, herpes simplex infections), hypersensitivity reactions (e.g. urticaria, dyspnoea).
Gastrointestinal disorders: Diarrhoea. General disorders and admin site conditions: Inj site reactions (e.g. erythema, pain). Musculoskeletal and connective tissue disorders: Arthralgia. Nervous system disorders: Headache. Skin and subcutaneous tissue disorders: Rash. |
MonitoringParameters
Conduct TB screening prior to initiation and periodically during treatment. Monitor for signs and symptoms of infection and active TB during and after treatment.
|
Drug Interactions
Enhanced immunosuppressive effects with belimumab, infliximab.
Potentially Fatal: May enhance adverse/toxic effects of live vaccines. |
Action
Description: Guselkumab is a recombinant human immunoglobulin G1 (IgG1 lambda) monoclonal antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23), a cytokine involved in the normal inflammatory and immune responses, thereby inhibiting the release of proinflammatory cytokines and chemokines.
Pharmacokinetics: Absorption: Bioavailability: Approx 49%. Time to peak plasma concentration: Approx 5.5 days. Distribution: Crosses placenta. Volume of distribution: Approx 13.5 L. Metabolism: Degraded via catabolic pathways into small peptides and amino acids. Excretion: Elimination half-life: Approx 15-18 days. |
Storage
Store between 2-8°C. Do not freeze. Protect from light.
|
ATC Classification
L04AC16 - guselkumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
|
References
Anon. Guselkumab. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 05/09/2019. Anon. Guselkumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/09/2019. Buckingham R (ed). Guselkumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/09/2019. Tremfya Injection (Janssen Biotech, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/09/2019.
|